Matches 1 - 50 out of 340 1 2 3 4 5 6 7 >


Match Document Document Title
US20150273064 Pharmaceutical Formulation Containing Gelling Agent  
Disclosed in certain embodiments is a controlled release oral dosage form comprising a therapeutically effective amount of a drug susceptible to abuse together with one or more pharmaceutically...
US20150265605 Pharmaceutical Formulation Containing Gelling Agent  
Disclosed in certain embodiments is a controlled release oral dosage form comprising a therapeutically effective amount of a drug susceptible to abuse together with one or more pharmaceutically...
US20090130197 EXTENDED RELEASE PELLET FORMULATION CONTAINING PRAMIPEXOLE OR A PHARMACEUTICALLY ACCEPTABLE SALT  
An extended release pellet comprising an active ingredient selected from pramipexole and the pharmaceutically acceptable salts thereof, and at least one release-modifying excipient.
US20170119664 CARBIDOPA/LEVODOPA GASTRORETENTIVE DRUG DELIVERY  
A gastroretentive drug formulation for the sustained release of an active agent in the gastrointestinal tract comprises internal layer or compartment comprising an active agent and one or more...
US20160120810 CRUSH RESISTANT DELAYED-RELEASE DOSAGE FORMS  
The invention relates to a dosage form comprising a physiologically effective amount of a physiologically active substance (A), a synthetic, semi-synthetic or natural polymer (C), optionally one...
US20160067199 NOVEL FORMULATION OF DICLOFENAC  
The present invention relates to methods for producing particles of diclofenac using dry milling processes as well as compositions comprising diclofenac, medicaments produced using diclofenac in...
US20160058716 PHARMACEUTICAL FORMULATION CONTAINING GELLING AGENT  
Disclosed in certain embodiments is a controlled release oral dosage form comprising a therapeutically effective amount of a drug susceptible to abuse together with one or more pharmaceutically...
US20160000712 Pharmaceutical Formulation Containing Gelling Agent  
Disclosed in certain embodiments is a controlled release oral dosage form comprising a therapeutically effective amount of a drug susceptible to abuse together with one or more pharmaceutically...
US20150359747 ABUSE-PROOFED DOSAGE FORM  
The invention relates to a dosage form that is thermoshaped without being extruded and that is safeguarded from abuse, comprising at least one synthetic or natural polymer having a breaking...
US20150273065 Pharmaceutical Formulation Containing Gelling Agent  
Disclosed in certain embodiments is a controlled release oral dosage form comprising a therapeutically effective amount of a drug susceptible to abuse together with one or more pharmaceutically...
US20150238561 Compositions of GnRH related compounds and processes of preparation  
The present invention provides compositions of GnRH related compounds that are suitable for oral administration, injectable administration and other forms of administration wherein the gelling...
US20150216807 SOLUBILIZED COQ-10  
The present invention is directed to compositions and methods of delivery of CoQ-10 solubilized in monoterpenes. Use of monoterpenes as dissolving agents, greatly effects the ability to...
US20150209318 PHARMACEUTICAL COMPOSITIONS CONTAINING DIMETHYL FUMARATE  
Provided herein are compositions containing compounds, or pharmaceutically acceptable salts, that metabolize to monomethyl fumarate with certain pharmacokinetic parameters and methods for...
US20150150978 DOSAGE THAT IS SAFEGUARDED FROM ABUSE  
The invention relates to a dosage form that is thermoshaped without being extruded and that is safeguarded from abuse, comprising at least one synthetic or natural polymer having a breaking...
US20150147391 Pharmaceutical Formulation Containing Gelling Agent  
Disclosed in certain embodiments is a controlled release oral dosage form comprising a therapeutically effective amount of a drug susceptible to abuse together with one or more pharmaceutically...
US20150132374 FORMULATIONS  
A modified release composition comprising cyclosporin A for oral administration. The composition may comprise a core and a modified release coating, wherein the core comprises a hydrogel-forming...
US20140370082 CYCLOSPORINE ANALOGUE MIXTURES AND THEIR USE AS IMMUNOMODULATING AGENTS  
The invention is directed to isomeric mixtures of cyclosporine analogues that are structurally similar to cyclosporine A. The mixtures possess enhanced efficacy and reduced toxicity over the...
US20140356294 DOSAGE THAT IS SAFEGUARDED FROM ABUSE  
The invention relates to a dosage form that is thermoshaped without being extruded and that is safeguarded from abuse, comprising at least one synthetic or natural polymer having a breaking...
US20140234410 COMBINATION PRODUCTS  
A pharmaceutical formulation comprises a plurality of seamless minicapsules having a diameter from 0.5 mm to 5 mm, at least some of the minicapsules containing a methyxanthine as one active...
US20140205659 CONTROLLED RELEASE PHARMACEUTICAL COMPOSITIONS COMPRISING A FUMARIC ACID ESTER  
The present invention relates to controlled release pharmaceutical compositions comprising fumaric acid ester(s) as active substance(s). The compositions are suitable for use in the treatment of...
US20140199388 CONTROLLED RELEASE PHARMACEUTICAL COMPOSITIONS COMPRISING A FUMARIC ACID ESTER  
The present invention relates to controlled release pharmaceutical compositions comprising fumaric acid ester(s) as active substance(s). The compositions are suitable for use in the treatment of...
US20140199387 CONTROLLED RELEASE PHARMACEUTICAL COMPOSITIONS COMPRISING A FUMARIC ACID ESTER  
The present invention relates to controlled release pharmaceutical compositions comprising fumaric acid ester(s) as active substance(s). The compositions are suitable for use in the treatment of...
US20140199386 CONTROLLED RELEASE PHARMACEUTICAL COMPOSITIONS COMPRISING A FUMARIC ACID ESTER  
The present invention relates to controlled release pharmaceutical compositions comprising fumaric acid ester(s) as active substance(s). The compositions are suitable for use in the treatment of...
US20140186437 ORAL DOSAGE FORMS WITH THERAPEUTICALLY ACTIVE AGENTS IN CONTROLLED RELEASE CORES AND IMMEDIATE RELEASE GELATIN CAPSULE COATS  
The present invention relates to oral dosage form with active agents in controlled release cores and in immediate release gelatin capsule coats.
US20140086847 DOSAGE FORM THAT IS SAFEGUARDED FROM ABUSE  
The invention relates to a dosage form that is thermoshaped without being extruded and that is safeguarded from abuse, comprising at least one synthetic or natural polymer having a breaking...
US20120177730 Chemosensory Receptor Ligand-Based Therapies  
Provided herein are methods for treating conditions associated with a chemosensory receptor, including diabetes, obesity, and other metabolic diseases, disorders or conditions by administrating a...
US20100151013 Gastric acid secretion inhibiting composition  
An oral pharmaceutical dosage form comprises pharmacologically effective amounts of an acid-susceptible proton pump inhibitor and an H2 receptor antagonist in combination with at least on...
US20080311187 CRUSH RESISTAN DELAYED-RELEASE DOSAGE FORM  
The invention relates to a dosage form comprising a physiologically effective amount of a physiologically active substance (A), a synthetic, semi-synthetic or natural polymer (C), optionally one...
US20080152704 Dosage Forms of Palonosetron Hydrochloride Having Improved Stability and Bioavailability  
Provided are solid oral dosage forms of palonosetron hydrochloride, methods of using the dosage forms to treat emesis, and methods of making the dosage forms. The dosage forms have improved...
US20080131501 Enhanced immediate release formulations of topiramate  
The present invention provides enhanced immediate release formulations of topiramate, in which 80% of the active ingredient is released in the period of time of not more than 30 min. These...
US20070202160 SOLID-STATE FORM OF CELECOXIB HAVING ENHANCED BIOAVAILABILITY  
The selective cyclooxygenase-2 inhibitory drug celecoxib is provided in amorphous form. Also provided is a celecoxib drug substance wherein the celecoxib is present, in at least a detectable...
US20170049769 Abuse Deterrent Compositions and Methods of Making Same  
This invention relates a therapeutic pharmaceutical composition comprising: a mixture including an opioid; polyethylene oxide in an amount of about 3 to about 40 wt % of the composition; a...
US20160317456 PHARMACEUTICAL COMPOSITIONS  
Pharmaceutical compositions containing a therapeutically active agent, a diffusion barrier coating and coating comprising a hydrophobic material.
US20160310559 Delayed Release Compositions of Linaclotide  
The present invention relates to delayed release pharmaceutical compositions comprising linaclotide or pharmaceutically acceptable salts thereof, as well as to various methods and processes for...
US20160030289 MANUFACTURE OF PEANUT FORMULATIONS FOR ORAL DESENSITIZATION  
The present application relates to a method for managing the development and manufacturing process of a therapeutically effective formulation. Peanut proteins are characterized from peanut flour...
US20160022588 ABUSE-PROOFED ORAL DOSAGE FORM  
The present invention relates to an abuse-proofed oral dosage form with controlled release of (1R,2R)-3-(3-dimethylamino-1-ethyl-2-methyl-propyl)phenol for once daily administration, which...
US20150320682 NANOPARTICULATE MEGESTROL FORMULATIONS  
The present invention is directed to nanoparticulate compositions comprising megestrol. The megestrol particles of the composition have an effective average particle size of less than about 2000 nm.
US20150010623 CONTROLLED RELEASE PREPARATIONS  
Controlled release preparations and soft capsules are provided. Also provided are emulsions and suspensions, including compositions and methods of manufacturing controlled release soft capsules,...
US20150004224 DPA-ENRICHED COMPOSITIONS OF OMEGA-3 POLYUNSATURATED FATTY ACIDS IN FREE ACID FORM  
DPA-enriched pharmaceutical compositions of polyunsaturated fatty acids in free acid form, therapeutic methods for their use, and processes for refining the compositions from fish oil are...
US20140248341 ALCOHOL RESISTANT ENTERIC PHARMACEUTICAL COMPOSITIONS  
Pharmaceutical formulations that resist ethanol-induced dose dumping and methods of use thereof.
US20140242159 Method for Preparing a Granulate Formulation of Pirfenidone and Pharmaceutically Acceptable Excipients  
A capsule formulation of pirfenidone is provided that includes pharmaceutically acceptable excipients. In one embodiment, this capsule formulation is capable of sustaining desirable...
US20130337058 Micronized Tanaproget and Compositions Containing Same  
The present invention provides compositions, desirably pharmaceutical compositions, containing micronized tanaproget. The compositions can also contain microcrystalline cellulose, croscarmellose...
US20130052263 PHARMACEUTICAL COMPOSITIONS WITH SYNCHRONIZED SOLUBILIZER RELEASE  
Pharmaceutical compositions with synchronized solubilizer release as well as various methods associated therewith, are disclosed and described. More specifically, the aqueous solubility of a drug...
US20110223244 ALCOHOL RESISTANT ENTERIC PHARMACEUTICAL COMPOSITIONS  
Pharmaceutical formulations that resist ethanol-induced dose dumping and methods of use thereof.
US20110182985 Solid Pharmaceutical Composition with Enhancers and Methods of Preparing thereof  
The present invention provides pharmaceutical compositions which are effective in providing therapeutically effective blood levels of a therapeutically active ingredient to a subject when...
US20050063913 Novel metaxalone compositions  
The present invention is directed to nanoparticulate compositions comprising metaxalone. The metaxalone particles of the composition have an effective average particle size of less than about 2...
US20170000733 PHARMACEUTICAL COMPOSITIONS OF AMORPHOUS DISPERSIONS OF DRUGS AND LIPOPHILIC MICROPHASE-FORMING MATERIALS  
A pharmaceutical composition comprises a solid amorphous dispersion comprising a low-solubility drug and a concentration-enhancing polymer and a lipophilic microphase-forming material....
US20160361274 MODIFIED RELEASE DOSAGE FORMS OF SKELETAL MUSCLE RELAXANTS  
A unit dosage form, such as a capsule or the like, for delivering a skeletal muscle relaxant, such as cyclobenzaprine hydrochloride, into the body in an extended or sustained release fashion...
US20160346216 COMPOSITION AND METHOD FOR AIDING SLEEP  
Described is a controlled-release formulation for treating disturbed sleep or insomnia in a subject. The formulation is formulated to release a compound or combination of compounds in sequence at...
US20160038411 PULSATILE GASTRIC RETENTIVE DOSAGE FORMS  
Dosage forms for delayed and pulsed release of therapeutic agents into the stomach are described. The dosage forms are gastric retentive dosage forms that achieve release of the therapeutic agent...

Matches 1 - 50 out of 340 1 2 3 4 5 6 7 >